Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zeprumetostat + azacitidine + mitoxantrone hydrochloride liposome
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
zeprumetostat + azacitidine + mitoxantrone hydrochloride liposome is a combination therapy being investigated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). The regimen consists of zeprumetostat, an oral small-molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2) developed by Jiangsu Hengrui Pharmaceuticals; azacitidine, a DNA methyltransferase inhibitor; and mitoxantrone hydrochloride liposome, a liposomal formulation of the cytotoxic agent mitoxantrone. This triple-drug combination is the subject of a Phase II clinical trial led by The First Affiliated Hospital of Soochow University, which aims to evaluate its efficacy and safety in patients who have failed at least one prior line of systemic therapy. Zeprumetostat itself received conditional approval in China in August 2025 for r/r PTCL as a monotherapy.
- Other names
- SHR2554 combinationSHR-2554 combinationSHR 2554 combination
02
Targets
DNADNMT (DNA methyltransferase)EZH2 (Histone-lysine N-methyltransferase EZH2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on zeprumetostat + azacitidine + mitoxantrone hydrochloride liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zeprumetostat + azacitidine + mitoxantrone hydrochloride liposome.